Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers

BEA-28Positive

AI Analysis

Summary

Beactica Therapeutics AB announced the selection of BEA-28 as a preclinical candidate for its TEAD programme targeting biomarker-selected cancers. The compound is designed as a first-in-class TEAD degrader.

Outcome Details

Preclinical candidate selection for TEAD programme

Importance:2/10

Sentiment:

0.50

preclinicalTEAD degraderprecision medicinefirst-in-classSweden

Related Companies

$SHWZ $SOBI.ST $TRAX

Read the original article

Published by PR Newswire Biotech on October 6, 2026 6:21 AM

Read Original